KWA
TAK icon

KCS Wealth Advisory’s Takeda Pharmaceutical TAK Stock Holding History

KCS Wealth Advisory’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-28,531
Closed -$505K – 456
2019
Q2 		$505K Sell
28,531
-9,863
-26% -$179K 0.4% 102
2019
Q1 		$782K Buy
+38,394
New +$773K 0.68% 68

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

KCS Wealth Advisory's TAK Position: Q3 2019 in Review

KCS Wealth Advisory sold out of Takeda Pharmaceutical (TAK) in Q3 2019, closing a stake of 28,531 shares — an estimated $505K sold.

KCS Wealth Advisory first reported a position in TAK in Q1 2019 and held it in 2 quarters. The position peaked at $782K in Q1 2019. 317 funds tracked by Wall St. Rank hold TAK as of Q3 2019.

  • KCS Wealth Advisory reported no remaining Takeda Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • KCS Wealth Advisory sold 28,531 Takeda Pharmaceutical shares in Q3 2019, an estimated $505K.
  • KCS Wealth Advisory first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 2 quarters.
  • KCS Wealth Advisory's Takeda Pharmaceutical position peaked at $782K in Q1 2019.
  • 317 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2019.

Based on KCS Wealth Advisory's 13F filing for Q3 2019, filed 29 Oct 2019.